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ABSTRACT
Extracellular ATP (eATP) accumulation within the tumor microenvironment 
(TME) has the potential to activate purinergic signaling. The eATP evoked signaling 
effects bolster antitumor immune responses while exerting direct cytotoxicity on 
tumor cells and vascular endothelial cells, mediated at least in part through P2X7 
receptors. Approaches to augment purinergic signaling in TME e.g. by ectonucleotidase 
CD39 blockade, and/or boosting P2X7 functional responses, might be used as 
immunomodulatory therapies in cancer treatment. In this study, we delineated the 
translatable strategy of hyperthermia to demonstrate impacts on P2X7 responsiveness 
to eATP. Hyperthermia (40°C) was noted to enhance eATP-mediated cytotoxicity on 
MCA38 colon cancer cells. Increased membrane fluidity induced by hyperthermia 
boosted P2X7 functionality, potentiating pore opening and modulating downstream 
AKT/PRAS40/mTOR signaling events. When combined with cisplatin or mitomycin 
C, hyperthermia and eATP together markedly potentiate cancer cell death. Our data 
indicate that clinically tolerable hyperthermia with modulated P2X7-purinergic 
signaling will boost efficacy of conventional cancer treatments.
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INTRODUCTION
Adenosine triphosphate (ATP) is well known 
to provide the intracellular energy currency of cells, 
but is also present at low levels in the extracellular 
space under physiological conditions. Higher levels of 
extracellular ATP are perceived as a danger signal by 
cells in pathological processes [1]. The presence of high 
levels of extracellular ATP has been noted in the tumor 
microenvironment [2, 3]. Such heightened pericellular 
ATP levels have been demonstrated to increase tumor 
cell death through multiple mechanisms inclusive of: 
augmentation of antitumor immunity, direct induction 
of tumor cell death, and blockade of tumor angiogenesis 
[4, 5].
Although antitumor actions of extracellular ATP 
may occur through activation of several type 2-purinergic 
receptors (P2R), P2X7 is thus far the most important ATP-
receptor [1, 5]. P2X7 is the only P2X receptor capable to 
form a membrane pore permeable to large molecules (up 
to 900 Da), resulting in tumor cell apoptosis [6].
Low levels of extracellular ATP that develop as a 
consequence of scavenging, or defective P2X7 activation 
per se, have been linked to immunosuppressive responses. 
These provoke cancer development by allowing tumor 
cells to escape from the P2X7 controlled pro-apoptotic 
mechanisms [7, 8]. Curiously, basal or low level activation 
of P2X7 receptor promotes tumor cell growth [9]. A 
therapeutic modality that increases P2X7 tumoricidal 
functions, thereby preventing cancer cell escape, would 
be an important advance.
We have recently highlighted the modulation of 
P2X7 receptor signaling in induction of cancer cell 
death and proposed the use of purine-related drugs 
as adjunctive agents in cancer therapy [4]. We have 
demonstrated that pulsed treatment of MCA38 colon 
cancer cells with high levels of ATP was able to induce 
cancer cell death, exclusively via P2X7 [4]. We have 
further delineated PI3K/AKT and AMPK-PRAS40-mTOR 
as the downstream pathways initiated by ATP-P2X7 
signals. These two signaling axes act synergistically to 
elicit maximal levels of tumor cell death by disrupting 
homeostatic cell growth and the process of autophagy.
More recently, we have also shown that high levels 
of extracellular ATP promote human cervical cancer cell 
death through a joint mechanism linked by both P2X7 
activation and associated adenosine formation [10]. 
Cells expressing high levels of P2X7 are susceptible to 
ATP-P2X7 cytotoxicity, whereas the death of cells with 
low P2X7 levels appeared to be caused by adenosine 
uptake and subsequent AMPK phosphorylation, dATP 
accumulation, p53 activation, as well as autophagy 
induction [10].
Interestingly, pore-forming activity of P2X7 has 
been linked to remodeling of membrane lipid rafts viz. 
the rate of agonist-evoked pore formation is enhanced 
by cholesterol depletion using methyl-β-cyclodextrin 
(MCD) whereas is inhibited by cholesterol loading [11]. 
Moreover, lipid raft remodeling can be induced by heat 
stress, non-proteotoxic membrane lipid-interacting 
chemicals, such as Bimoclomol, or the membrane fluidizer 
benzyl alcohol (BA) [12, 13]. These so-called “membrane-
lipid therapy” promote changes in the nanostructure and 
physicochemical state of plasma membranes by interfering 
with protein and lipid interactions, thereby altering cell 
transmembrane signals [13]. However, whether such 
membrane-lipid therapies impact P2X7 functionality, and 
to what extent this is feasible, remain elusive.
Here, we demonstrate that mild heat stress (or 
hyperthermia; 40°C) augments ATP agonist efficacy 
thereby stimulating P2X7 pore opening and dilatation. 
Ultimately, this leads to dramatically enhanced MCA38 
colon cancer cell death, as mediated through AKT/
PRAS40/mTOR signaling. Hyperthermia-induced 
increases in membrane fluidity facilitate P2X7 pore 
formation and promote cell death. Furthermore, we have 
also shown that cisplatin or mitomycin C in combination 
with hyperthermia and extracellular ATP is more effective 
in inducing cancer cell death. Our results suggest the 
potential utility of P2X7 hyperactivation by hyperthermia 
as an adjunct therapy in the treatment of cancer.
RESULTS
Hyperthermia increases ATP tumoricidal activity 
via P2X7-AKT/PRAS40/mTOR signaling
We have previously shown that, at 37°C, 1 mM 
ATP will rapidly cause cytotoxicity in MCA38 colon 
cancer cells at 30 min [4]. Herein, we have investigated 
whether hyperthermia would sensitize cancer cells to ATP 
cytotoxicity. We first titrated growth responses of wild 
type (WT) MCA38 cells to increased ATP levels (ranging 
from 1, 2.5 and 5 mM) for 15 min at 37°C, 40°C or 42°C. 
As shown in Supplementary Figure 1, 42°C treatment 
was capable to promote cancer cell death per se. ATP 
cytotoxicity was selectively and dramatically enhanced by 
mild heat stress (hyperthermia; 40°C) in a dose-dependent 
manner (Figure 1A). In contrast, at 37°C, cytotoxicity 
was only noted with much higher concentration of ATP 
(5 mM). Therefore, 1 mM of ATP for 15 min and the 
temperature of 40°C were chosen for the hyperthermia 
experimentation, unless otherwise stated. We observed 
that elevation of cytotoxicity induced by combination of 
ATP and hyperthermia was associated with increased cell 
death (Figure 1B; upper panel) and cell shrinkage (Figure 
1B; middle panel). We also found that ATP/hyperthermia-
evoked cell death has both apoptotic and necrotic 
characteristics (Figure 1B; bottom panel). Moreover, such 
antitumor activity was near completely counteracted by 
co-treatment with APT102, a soluble ectonucleotidase, 
when cells were exposed to ATP (1 mM) for 30 min, either 
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Figure 1: Hyperthermia potentiates ATP cytotoxicity in a P2X7-dependent manner. (A-B) MCA38 wild type (WT) cells 
were treated with exogenous ATP at indicated concentrations and temperatures for 15 min. Cells treated with media served as control 
(Ctrl). Cell viability was determined using CCK-8 (A) and images of live cells were captured by Celigo (upper) and cell apoptosis/
necrosis was evaluated by FACS (middle and bottom) (B). (C) Cells were left untreated or pre-treated with 2.5 μg/ml of APT102 (soluble 
ectonucleotidase CD39) for 30 min before exposed to ATP 1 mM for 30 min at indicated temperatures. Cell viability was measured 24 hr 
later. (D-E) MCA38 P2X7 KD (P2X7-deficient) and NC (negative control) cells were treated with ATP (1 mM for 15 min) at 37°C or 40°C. 
AKT/PRAS40/mTOR signaling pathway was analyzed by Western blotting (D) and cell viability was evaluated after 24 hr (E). *p < 0.05 
as compared to control (one-way ANOVA, followed by Tukey pos-test). Bars, 50 μM.
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at 37°C or 40°C (Figure 1C), suggesting the exclusive 
involvement of ATP in antitumor actions under these 
experimental settings.
We established previously that ATP induces MCA38 
cancer cell death through two P2X7-mediated intracellular 
signaling networks: PI3K/AKT and AMPK-PRAS40-
mTOR [4]. We next examined whether there was an 
exclusive link between hyperthermia and P2X7 signaling 
by employing the P2X7-deficient MCA38 cell line (P2X7 
KD) [4].
We first confirmed resistance of P2X7 KD cells to 
cytotoxicity induced by ATP and hyperthermia. In the 
negative control cell line (NC), as linked to cell death, 
we noted additive effects of hyperthermia on the two 
ATP-P2X7 signaling axes: 40°C treatment decreased 
phosphorylation of both AKT and mTOR pathway 
components including PRAS40, S6K and S6 (Figure 1D 
and 1E). These effects were not seen in the P2X7 KD cell 
line (Figure 1D and 1E).
Hyperthermia facilitates ATP cytotoxicity by 
increasing P2X7 functionality
Next, we evaluated the impact of hyperthermia on 
P2X7 functionality including pore formation capacity, 
Ca2+ influx, and associations with pannexin or connexin 
channels. First, ethidium bromide uptake assay was 
performed to measure the membrane pore-opening activity 
of P2X7 in a non-selective manner. We observed that ATP 
markedly stimulates ethidium bromide uptake when cells 
were incubated at 40°C (Figure 2A).
Second, two chemical compounds that differently 
alter cytosolic Ca2+ levels: BAPTA-AM, a selective cell 
permeable calcium chelator that depletes Ca2+ intracellular 
stores, and thapsigargin (TG), a potent inhibitor of 
endoplasmic reticulum Ca2+-ATPase causing an immediate 
increase in cytoplasmic Ca2+ levels, were employed to 
examine changes in the ATP-P2X7 intracellular signaling 
pathway upon hyperthermia treatment. As shown in 
Figure 2B, neither BAPTA-AM nor TG was able to block 
hyperthermia-induced ATP-P2X7-AKT/PRAS40/mTOR 
signaling transduction. Of note, prevention of extracellular 
Ca2+ influx with EDTA also fails to counteract ATP 
cytotoxicity at 40°C (Supplementary Figure 2). Moreover, 
carbenoxolone (CBX), a pharmacological inhibitor of 
pannexin/connexin channels that are often linked to P2X7 
activation, also failed to block the hyperthermia-associated 
changes to the ATP-P2X7 signaling cascade (Figure 2B).
It is known that non-selective pore opening upon 
P2X7 activation facilitates cytosolic adenine nucleotide 
efflux into the extracellular space [4]. We then assessed 
levels of both extracellular and intracellular adenine 
nucleotides in our experimental settings by HPLC. 
We found that co-treatment of ATP with hyperthermia 
significantly increased levels of extracellular adenine 
nucleotides (inclusive of ATP, ADP and AMP), 
accompanied with concomitant decreases in intracellular 
levels of ATP (Figure 2C). Such phenomena were not 
seen in cells deficient of P2X7 (Figure 2C). Of note, basal 
levels of extracellular nucleotides were not altered by the 
changes in temperatures (data not shown).
These data suggest that hyperthermia/ATP-evoked 
pore formation is an intrinsic property of P2X7 receptor 
that is independent of calcium signaling and pannexin/
connexin channels.
Hyperthermia-induced P2X7 sensitivity to 
ATP is not associated with lipid raft cholesterol 
content
It has been demonstrated that membrane interaction 
of P2X7 with lipid rafts regulates the receptor channel 
properties [11], and heat stress perturbs lipid raft integrity 
[12, 13]. As such, we next evaluated the role of cholesterol 
within lipid rafts in hyperthermia and ATP-mediated 
hyperactivation of P2X7.
First, we examined the involvement of cholesterol, 
an essential component of plasma membrane lipid rafts, 
in hyperthermia/ATP-induced cytotoxicity. Cells were 
pre-treated with two chemical cholesterol disruptors: 
methyl β-cyclodextrin (MCD), which depletes lipid rafts 
cholesterol or filipin, which is highly fluorescent and binds 
specifically to cholesterol, before cells were exposed to 
ATP and/or hyperthermia. In Supplementary Figure 3A, 
we show that filipin forms a multimeric globular complex 
with membrane cholesterol, whereas MCD (10 mM) 
effectively depletes rafts of cholesterol. We observed that 
MCD or filipin had no effects on ATP cytotoxicity at 40°C 
(Figure 3A).
Alternatively, stabilization of lipid rafts by 
loading cells with soluble cholesterol also failed to alter 
ATP tumor-killing activity (Figure 3B), indicating that 
cholesterol content within lipid rafts is not responsible 
for controlling P2X7 functionality. In addition, 
immunoprecipitation assays suggested there were no 
physical interactions between P2X7 and the two lipid 
raft markers caveolin-1 or flotillin-2 (Supplementary 
Figure 3B).
However, interestingly, combination of 
hyperthermia and ATP indeed led to reorganization of 
membrane cholesterol (Figure 3C), indicating that changes 
in the plasma membrane structure per se may modulate 
P2X7 function.
Hyperthermia-induced membrane fluidity is 
responsible for enhanced P2X7 sensitivity to ATP
It is known that, besides lipid raft reorganization, 
alterations in the nanostructure and physicochemical state 
of plasma membrane e.g. membrane fluidity may also 
interfere with protein and receptor functions [12, 13]. We 
thus replaced hyperthermia with a membrane fluidizer 
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Figure 2: Hyperthermia increases ATP-tumor killing activity by enhancing P2X7 pore formation independently of 
Ca2+ influx and pannexin/connexin interaction. (A) P2X7 functionality upon ATP/hyperthermia treatment measured by etidium 
bromide (EtBr) uptake. Cells were left untreated or treated with ATP (1 mM) for 15 min at 37°C or 40°C, followed by whole cell 
fluorescence measurement (AUF), as described in Material and Methods. (B) Cells were pre-incubated with BAPTA-AM, thapsigargin 
(TG) or Carbenoxolone (CBX) prior to heat-ATP pulse treatment, followed by western blot analysis of AKT/PRAS40/mTOR signaling 
pathway. Cells treated with media served as control. (C) NC (negative control) and P2X7 KD (P2X7-deficient) cells were exposed to ATP 
for 15 min at 37°C or 40°C and extracellular and intracellular adenine nucleotide levels were determined by HPLC. *p < 0.05 in contrast 
to control (one-way ANOVA, followed by Tukey pos-test, mean ± SD).
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benzyl alcohol (BA) at 37°C in our experimental settings 
to test if BA treatment could mimic these hyperthermia 
effects on P2X7 functionality initiated by ATP, as 
described above. As shown in Figure 4A, in NC cells, BA 
increased ATP cytotoxicity at 37°C in a dose-dependent 
manner. This is concurrent with increased cell shrinkage 
(Figure 4B, upper and middle) and cell apoptosis/necrosis 
(indicated by percentages of Annexin-V+/PI+ cells) (Figure 
4B, bottom right) as well as blockade of AKT/PRAS40/
mTOR signaling (Figure 4C). And such effects were near 
completely blocked in P2X7 KD cells. Moreover, co-
treatment of BA with ATP at 37°C resulted in cholesterol 
rearrangement in the plasma membrane that is similar 
to ATP effects at 40°C (Figure 4D). In parallel, neither 
cholesterol disruption by filipin nor cholesterol loading 
was able to counteract BA-induced ATP cytotoxicity at 
37°C (Supplementary Figure 4).
Taken together, these results imply that enhancements 
in membrane fluidity caused by hyperthermia augment 
P2X7 receptor function.
Hyperthermia and extracellular ATP potentiate 
chemotherapy cytotoxicity, eliciting maximal cell 
death
Next, we investigated the therapeutic potential 
of combining hyperthermia and ATP with conventional 
chemotherapeutic drugs (i.e. cisplatin or mitomycin 
C). Cells were exposed to cisplatin or mitomycin C 
prior to ATP and/or hyperthermia treatment. We noted 
that cisplatin induced cancer cell death in a dose-
dependent manner, while mitomycin C alone produced 
a slight cytotoxic effect only at the higher concentration 
(Figure 5A). Combination of both drugs with hyperthermia 
Figure 3: Hyperthermia-increased P2X7 functionality is independent of lipid rafts. (A-B) MCA38 cells were treated with 
methyl β-cyclodextrin (MCD) (left) or filipin (right) (A) or cholesterol (B), before being pulse treated with ATP (1 mM) for 15 min at 40°C. 
24 hr later, cell viability was evaluated. Cells treated with media served as control (Ctrl). (C) Cholesterol staining with filipin showing 
cholesterol rearrangement at the plasma membrane after treatment with hyperthermia and ATP. *p < 0.05 in contrast with control (two-way 
ANOVA, followed by Bonferroni pos-test, mean ± SD). Bars, 20 μM.
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Figure 4: The membrane fluidizer benzyl alcohol (BA) acts similarly as hyperthermia leading to P2X7 hyperactivation 
at 37°C. NC (negative control) or P2X7 KD (P2X7-deficient) cells were exposed to BA alone or together with ATP for 15 min at 37°C 
(in order to mimic the heat effect per se) or 40°C. Cells treated with media served as control (Ctrl). (A) Cell viability and (B) images of 
live cells (upper panel) and FACS analyses of NC cells (middle and bottom panels) were determined. (C) Western blot analysis of AKT/
PRAS40/mTOR pathway components was performed immediately after treatment. (D) Re-organization of cholesterol-rich microdomains 
in co-treated NC cells was visualized using filipin. *p < 0.05 when compared to control (two-way ANOVA, followed by Bonferroni pos-
test, mean ± SD). Bars, 50 μM (B) and 20 μM (D).
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and extracellular ATP exhibited additive effects on their 
cytotoxicity (Figure 5A and 5B). Indeed, this cumulative 
effect was more pronounced when cells were exposed to 
lower concentrations of cisplatin and all concentrations 
Figure 5: Combination of hyperthermia and ATP with chemotherapy drugs enhances the therapeutic efficacy. (A-
B) MCA38 WT cells were left untreated or treated with cisplatin or mitomycin C at the indicated concentrations overnight prior to ATP 
pulse treatment (ATP 1 mM, 15 min). Cell viability was evaluated after 24 hr. Overall response (A) and drug dose response curve at 40°C 
(B) were analyzed. (C) Schematic illustration showing the use of hyperthermia with ATP as a new approach to elicit maximal tumor cell 
death in association with traditional chemotherapy. Hyperthermia, by promoting plasma membrane fluidity, increases P2X7 sensitivity to 
ATP and therefore enhances ATP tumor-killing activity. The combination of hyperthermia, ATP and conventional chemotherapy would 
consequently elicit maximal tumor cell death while circumventing side effects of high dose of cytotoxic drugs. *p < 0.05 when compared 
cells treated with ATP to cells without ATP treatment (two-way ANOVA, followed by Bonferroni pos-test, mean ± SD).
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of mitomycin C (Figure 5B), suggestive of the potential 
utility of hyperthermia and ATP in increasing therapeutic 
efficacy of both drugs while decreasing side effects caused 
by higher chemotherapy dosage.
Collectively, our data bring a new insight into 
cancer therapeutics: combination of hyperthermia with 
ATP or a purine-related drug as an adjunctive therapy 
to elicit maximal tumor cell death while circum-
venting side effects of chemotherapy (as illustrated in 
Figure 5C).
DISCUSSION
It has been proposed that high levels of extracellular 
ATP accumulate within tumor sites, post radiation and 
chemotherapy [3, 14]. These high levels of extracellular 
ATP in the tumor microenvironment inhibit tumor growth 
through the P2X7 receptor, i.e. stimulating antitumor 
immune responses via P2X7-NLRP3 inflammasome 
activation [14–16] as well as exerting P2X7-directed 
cytotoxicity in tumor cells and tumor vascular endothelial 
cells (thereby limiting angiogenesis) [4, 7, 8, 10, 17–25]. 
Therefore, maintaining extracellular ATP at high levels 
in tumor tissues and/or increasing P2X7 functionality 
might be effective approaches in enhancing the efficacy 
of traditional cancer therapies.
Local (or superficial) hyperthermia has been used 
as adjuvant to treat melanoma [26–28]. The clinical use 
of hyperthermia for cancer either alone or in combination 
with radiotherapy or chemotherapy has been exploited 
with mixed effects [28–31]. Improved clinical outcomes 
have been noted for many types of cancer including 
prostate [32, 33], breast [34, 35], cervix [36, 37] as well 
as head and neck cancer [38, 39]. Extracorporeal shock 
wave therapy (ESWT) is another therapeutic tool utilizing 
concurrent hyperthermia to treat breast cancer-related 
lymphedema [40, 41].
Although still controversial, combinations of hyper-
thermia with conventional cancer therapies appear to 
contribute to improved control, cure and/or palliation of 
certain cancers. Synergistic effects of hyperthermia with 
chemotherapy are still considered as options in isolated 
limb perfusion and intraperitoneal chemotherapy for 
sarcoma and melanoma [28, 42, 43].
Herein, we have identified a novel strategy utilizing 
hyperthermia that we show to augment ATP-elicited 
P2X7 functionality thereby maximizing induction 
of cancer cell death. We have further delineated the 
underlying molecular mechanisms that could boost 
effectiveness of chemotherapies such as cisplatin and 
mitomycin C.
Specifically, we found that hyperthermia effectively 
sensitizes P2X7 receptor functionality by altering 
membrane fluidity in response to tumoricidal ATP in 
MCA38 colon cancer cells. This effect is mediated 
through the two P2X7 downstream signaling: PI3K/
AKT and mTOR that we recently identified [4]. There 
is growing evidence linking the cellular response to heat 
stress to changes in lipid composition and architecture 
of plasma membranes [12]. Nagy et al. [12] showed that 
either thermal stress or the membrane fluidizer, benzyl 
alcohol (BA), was able to produce profound alterations 
in the plasma membrane microdomains and thereby 
generate stress signal to activate Hsp genes. In this study, 
we demonstrated that, at 37°C, BA was able to reproduce 
the hyperthermia effect in potentiating ATP-P2X7 induced 
cancer cell death, linking increases in membrane fluidity 
to enhanced P2X7 functionality. Despite hyperthermia 
and BA being able to activate Hsp gene and increase 
HSP expression [12, 13, 44], we were unable to observe 
any HSP modification or interaction with P2X7 in our 
experimental settings (not shown). This effect was not seen 
with ethyl alcohol (not shown), which is not considered as 
a membrane fluidizer. Ethyl alcohol does however have 
a role in inhibiting NLRP3 inflammasome activation, 
attenuating IL-1β and caspase-1 cleavage and secretion – 
pathways related to P2X7 receptor that controls immune 
system activation [45].
Changes in temperature can also alter solubility, 
redistribution and activity of lipid raft proteins [46, 47]. 
Evidences for the involvement of P2X receptors in lipid 
raft biology are emerging [48, 49] and the presence 
of P2X7 receptor in this lipid structure has also been 
described [11, 50, 51]. Accordingly, P2X7 association 
with lipid rafts varies by cell type. When present in non-
raft compartments, P2X7 seems to have increased ion 
channel activity. In contrast, P2X7 is conferred with a 
more resistant mode of gating when localized in lipid rafts 
[11, 50, 51]. In MCA38 cells, P2X7 receptor appears to be 
present at the non-raft compartments of plasma membrane 
and its activation occurs independently of cholesterol lipid 
rafts.
Furthermore, we have demonstrated that hype-
rthermia and extracellular ATP have the potential to 
synergistically increase cytotoxicity of cisplatin and 
mitomycin C, maximizing tumor cell death. Our data 
not only reinforce the possible justification of the use of 
hyperthermia as an adjunctive modality to treat cancer, but 
also provide a new insight into such treatment option with 
detailed molecular underpinnings.
On an important note, this strategy would only be 
applicable for tumor cells expressing the P2X7A receptor 
splice variant, which is the well-characterized full-length 
receptor capable of inducing pore formation and apoptosis 
[52]. Tumors cells expressing truncated/defective P2X7 
variant might fail to undergo cell death even with agonist 
stimulus [53–56].
Taken together, our work highlights the importance 
of in vivo studies to validate the therapeutic potential of 
hyperthermia, in combination with high levels of ATP or 
purine-related drugs, to achieve maximal efficacy of more 
standard cancer treatments.
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MATERIALS AND METHODS
Reagents and antibodies
Carbenoxolone (CBX), BAPTA-AM and 
thapsigargin (TG) were purchased from Tocris Bioscience 
(Ellisville, MO). APT102, the recombinant form of soluble 
CD39, was kindly provided by Dr. Ridong Chen at APT 
Therapeutics Inc. (St. Louis, MO). All other chemicals and 
cell culture media were from Sigma-Aldrich (St. Louis, 
MO) and other culture reagents from Life Technologies 
(Carlsbad, CA), unless otherwise stated.
Rabbit anti-mouse P2X7 antibody (#APR-004) 
was obtained from Alomone labs (Jerusalem, Israel); 
beta-actin (AC-15, #ab6276) from Abcam (Cambridge, 
MA); Flotillin-2 (B6, #sc-28320) from Santa Cruz 
Biotechnology, Inc. (Dallas, TX); Caveolin-1 (7C8, 
#NB100-615) from Novus Biologicals (Littleton, CO); 
phospho-AKT (S473) (#9271), phospho-PRAS40 (T246) 
(#2997), phospho-S6K (T389) (#9205), phospho-S6 
(S235/236) (#2211) from Cell Signaling Technology 
(Danvers, MA); HRP-conjugated goat anti-mouse 
(#31438), donkey anti-rabbit (#31458) and mouse anti-
goat IgG (#31400) and the SuperSignal West Femto 
Maximum Sensitivity Substrate reagents (#PI-34096) were 
from Thermo Scientific (Rockford, IL).
Tumor cell lines
Syngeneic C57BL/6 murine MCA38 colon cancer 
cells (a gift of Dr. Nicholas P. Restifo, National Cancer 
Institute) were kindly provided by Dr. Alan B. Frey 
at New York University School of Medicine [4, 24, 
57]. Cells were also tested for Mycoplasma and other 
infections by mouse IMPACT III PCR Profile via RADIL 
(Columbia, MO). Cells were maintained in culture flask 
in RPMI-1640 medium supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin-streptomycin at 37°C 
in a 5% CO2 atmosphere at 100% humidity. Generation of 
P2X7 knockdown cell line has been previously established 
[4]. Selection medium contains 3 μg/ml of puromycin. 
P2X7-defiecient (P2X7 KD) cells were infected with 
mouse P2X7 shRNA and negative control (NC) cells were 
infected with an empty shRNA vector control.
Hyperthermia treatment
MCA38 cells were pulse-treated with medium 
or ATP for 15-30 min at 37°C (incubator) or 40°C 
(water bath) with 5 min pre-incubation. This mild 
heat temperature was chosen considering the 
increased cytotoxicity caused by higher temperatures 
(Supplementary Figure 1). Also, according to Gombos et 
al [13], at 39.5°C, heat-induced lipid raft destabilization 
was seen after 10 min of thermal stress and a spontaneous 
recovery of raft integrity occurred in 45 min. As such, the 
time course of 15-30 min is adequate to study thermal 
stress-induced plasma membrane destabilization.
Antagonist/drugs/plasma membrane disturbance-
treatments
Cells were pre-incubated with antagonist 
carbenoxolone (100 μM), BAPTA-AM (10 μM), 
thapsigargin (100 nM), and EDTA (0.6 mM) for 30 min, 
and with soluble CD39 APT102 (2.5 μg/ml) for 15-
30 min, before being exposed to pulse treatment with 
ATP or control medium. Concentration and incubation 
time for APT102 was based on our previous work [58], 
which is sufficient to promote total ATP degradation. 
The cholesterol depleting agents, Methyl-β-cyclodextrin 
(MCD; 10 mM) or Filipin (10 μM), were incubated for 
20 min and removed before ATP treatment. Cholesterol 
loading at the plasma membrane was obtained by adding 
water-soluble cholesterol at 100 μg/ml for 30 min before 
and during ATP exposure. The membrane fluidizer 
benzyl alcohol (BA), a documented nondenaturant, was 
added together with ATP for 15 min in order to mimic 
the hyperthermia effect per se. The chemotherapy drugs 
Cisplatin and Mitomycin C were added at different 
concentrations overnight prior to ATP pulse treatment. All 
compounds were pre-mixed in complete culture medium 
(RPMI + 10% FBS) at their final concentrations tested 
before incubation with the cells.
Cell viability measurements
Cells (7.5 × 103) were seeded into 96-well plates and 
cultured for 24 hr. Cells were then treated as described 
above, replaced with fresh culture media, and grown for 
additional 24 hr. Cells viability was evaluated using Cell 
Counting Kit-8 (CCK-8, Dojindo Molecular Tech. Inc., 
Rockville, MD) that measures the activity of cellular 
dehydrogenases (correlating with cell proliferation), as 
previously established [24, 59].
Annexin V and propidium iodide (PI) staining
Phosphatidylserine externalization was determined 
by the annexin fluorescence signal of an annexin 
V-fluorescein isothiocyanate conjugate (BioLegend Inc, 
San Diego, CA) according to the manufacturer’s protocol. 
Immediately after treatment, cells were trypsinized and 
centrifuged for 5 min at 1200 rpm, and the supernatant 
was discarded. Cells were resuspended in Annexin V 
Binding Buffer at a concentration of 0.25-1.0 × 107 cells/
ml and then an aliquot of 100 μl was taken and incubated 
with 5 μl of FITC-Annexin V and 10 μl of PI for 15 min at 
room temperature in the dark. Samples were analyzed on 
BD FACS LSR II cytometer (BD Bioscience, San Diego, 
CA) using FlowJo V.10 software for analysis (Tree Star 
Inc, Ashland, OR).
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Analysis of intracellular and extracellular 
nucleotide levels by high-performance liquid 
chromatography
Intracellular and extracellular levels of ATP, ADP, 
and AMP were determined by high performance liquid 
chromatography (HPLC) as previously described [59–
61] with slight modifications. Cells were seeded into 35 
mm × 10 mm dishes in culture media and grown for 24 
hr until reach 70% of confluence. Cells were then treated 
with ATP (1 mM) or medium in a final volume of 2 ml for 
15 min, at 37°C or 40°C. The supernatant was removed, 
transferred to a new tube and centrifuged at 2,000 rpm 
for 10 min at 0°C. A new supernatant aliquot was taken, 
centrifuged at 5,000 rpm for 5 min at 0°C, precipitated 
by 5% of 8 M perchloric acid (PCA) and stored at -80°C 
for subsequent HPLC analyses. The remaining cells 
were washed with ice-cold HBSS five times to remove 
excess extracellular ATP. Some wells were lysed with 
130 μl of protein lysis buffer for protein concentration 
measurement; and some wells were harvested with 
600 μl of HBSS containing 5% of 8 M PCA and then 
subjected to three frozen-thaw cycles. Cells were then 
scraped, transferred to a 1.5 ml Eppendorf tube, pulse 
sonicated on ice, and then stored at -80°C for subsequent 
HPLC analysis. 40 μl of each sample were analyzed 
using a Waters 484 system (Waters Corporation, Milford, 
MA) as previously described [59–61].
Ethidium bromide uptake assay
This assay was performed as established 
previously [4, 62] with slight modifications. Briefly, 
cells (1.5× 104) were seeded into black 96-well 
plates. 24 hr later, cells were washed once with HBSS 
containing Ca2+/Mg2+ and incubated with 1.27 μM of 
ethidium bromide (a cell impermeable organic dye) 
in the absence or presence of ATP (1 mM) for 15 min 
at 37°C or 40°C, followed by whole cell fluorescence 
measurement (in arbitrary units of fluorescence, AUF) 
at 544/610 nm excitation/emission using the SoftMax 
Pro software on a SpectraMax M5 Microplate Reader 
(Molecular Devices, Sunnyvale, CA).
Western blotting
Cells were maintained in 35 mm × 10 mm dishes 
in culture media for 24 hr until reach 70% of confluence. 
Cells were treated with freshly made compounds and the 
reaction was stopped immediately by washing the cells 
with ice-cold PBS three times. Cells were then lysed in 
ice-cold modified-RIPA buffer (50 mM Tris-HCl, pH 7.4; 
1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl) 
supplemented with Protease and Phosphatase Inhibitor 
Cocktails (Thermo Scientific). The lysates were kept on 
ice for at least 30 min and then centrifuged at 14,000 
rpm for 20 minutes at 4°C. The measurement of protein 
concentrations and detailed procedures of immunoblotting 
were described previously [59, 63].
Immunoprecipitation
Cells were seeded into 100 mm × 20 mm dishes 
and kept in culture media until reach 80% of confluence. 
Cells were then treated and the reaction was stopped 
immediately by washing the cells with ice-cold PBS three 
times. Cell lysate was obtained as described in Western 
Blotting section. 150 μg of total cellular protein was 
incubated with 2 μl of P2X7 or Caveolin-1 antibody or 
10 μl of Flotillin-2 antibody with an end-over-end rotation 
at 4°C for 4 hr. Then, 20 μl of Protein G-Sepharose fast 
flow (Sigma Aldrich) were added into each mixture and 
incubated at 4°C on a rotating device overnight. The next 
day, the mixture were centrifuged at 2500 rpm, for 5 min 
at 4°C, washed three times with lysis buffer, eluted with 
2X SDS reducing sample buffer (Bio-Rad, Hercules, CA) 
containing 2% of 2-mercaptoethanol and resolved on a 
4-12% gradient SDS-page gel (Bio-Rad, Hercules, CA) 
according to western blot methods.
Filipin staining
Cells were seeded into 24-well plates at a low 
confluence and cultured over a cover slip for 3 days until 
reach 50% of confluence. Then, cells were treated with 
medium or ATP (1 mM) for 15 min at 37°C or 40°C. The 
supernatant was removed and cells were fixed with 2% 
paraformaldehyde (PFA) (Electron Microscopy Sciences, 
Hatfield, PA). Fixed cells were incubated with filipin 
(0.5 mg/ml) in PBS for 60 min [64], followed by two 
washes with PBS and two washes with distilled water. 
Cell-containing coverslips were then dried, mounted in 
a microscope glass slide and visualized/analyzed using a 
Zeiss AxioVert 200M Inverted Fluorescent Microscope 
(Peabody, MA). Pictures were taken at 40X magnification.
Statistical analyses
Statistical analyses were performed using Prism 
5 (GraphPad, La Jolla, CA). Data are expressed as 
percentage of control and presented as mean ± SD of at 
least three independent experiments. Statistical analyses 
for comparison among multiple groups were performed 
by one-way analysis of variance (ANOVA), followed 
by a Tukey post-hoc test. When more than one molecule 
was mixed to the same well at the same time, a two-way 
ANOVA was performed, followed by a Bonferroni post-
test. Values were considered significant at p < 0.05.
Abbreviations
ADP, adenosine diphosphate; AMP, adenosine 
monophosphate; ATP, adenosine triphosphate; APT102, 
soluble ectonucleotidase CD39; BAPTA-AM, 1,2-Bis(2-
Oncotarget67265www.impactjournals.com/oncotarget
aminophenoxy)ethane-N,N,N′,N′-tetra acetic acid 
tetrakis(acetoxymethyl ester); BA, benzyl alcohol; 
CBX, carbenoxolone; eATP, extracellular ATP; EDTA, 
ethylenediamine tetraacetic acid; HPLC, high performance 
liquid chromatography; MCD, methyl-β-cyclodextrin; NC, 
negative control cell line infected with an empty shRNA 
vector control; P2R, type 2-purinergic receptors; P2X7 
KD, P2X7-deficient MCA38 cell line; PCA, perchloric 
acid; PFA, paraformaldehyde; PI, propidium iodide; TG, 
thapsigargin; TME, tumor microenvironment; WT, wild 
type.
Author contributions
Conceptualization, P.A.M., Y.W. and S.C.R.; 
Methodology, P.A.M., S.B., L.E.B.S., H.Z., J.Z., W.J., 
Y.W., and S.C.R.; Investigation, P.A.M., S.B., L.E.B.S., 
Y.W., and S.C.R.; Formal analysis, P.A.M. and S.B.; 
Writing – Original Draft, P.A.M.; Writing – Review & 
Editing, P.A.M., M.R.W., G.L., A.B., Y.W., and S.C.R.; 
Funding Acquisition, Y.W. and S.C.R.; Resources, Y.W. 
and S.C.R.; Supervision, Y.W. and S.C.R.
ACKNOWLEDGMENTS
We sincerely thank Dr. Ridong Chen from APT 
Therapeutics, Inc. for providing APT102.
CONFLICTS OF INTEREST
The authors declare no competing or financial 
interests.
FUNDING
This work has been supported by the National 
Institute of Health awards P01HL107152 and R21 
CA164970; grants from the Ben and Rose Cole 
Charitable PRIA foundation, generosity of the family of 
Jane O. Siegel and the Leona M. and Harry B. Helmsley 
Charitable Trust to S.C.R., as well as the Charlotte F. 
& Irving W. Rabb Research Award to Y.W. together 
with the Doctoral scholarship from Coordenação 
de Aperfeiçoamento de Pessoal de Nível Superior 
(CAPES) and Fundação Lemann/Brazil to the first 
author P.A.M.
REFERENCES
1. Roger S, Jelassi B, Couillin I, Pelegrin P, Besson P, Jiang 
LH. Understanding the roles of the P2X7 receptor in solid 
tumour progression and therapeutic perspectives. Biochim 
Biophys Acta. 2015; 1848:2584-602.
2. Mathew R, Karantza-Wadsworth V, White E. Role of 
autophagy in cancer. Nat Rev Cancer. 2007; 7:961-7.
3. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, 
Di Virgilio F. Increased level of extracellular ATP at tumor 
sites: in vivo imaging with plasma membrane luciferase. 
PLoS One. 2008; 3:e2599.
4. Bian S, Sun X, Bai A, Zhang C, Li L, Enjyoji K, Junger 
WG, Robson SC, Wu Y. P2X7 integrates PI3K/AKT and 
AMPK-PRAS40-mTOR signaling pathways to mediate 
tumor cell death. PLoS One. 2013; 8:e60184.
5. Feng L, Tapper EB, Sun X, Gehring M, Robson SC, Wu 
Y. (2014). Purinegic Modulation and CD39/ENTPD1 in 
Cancer. In: Atta-ur-Rahman, Iqbal Choudhary M (eds) 
Frontiers in Anti-Cancer Drug Discovery, Bentham Science 
Publishers, Beijing, China, pp 229-292.
6. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli 
M, Wieckowski MR, Pinton P, Rizzuto R, Di Virgilio 
F. Basal activation of the P2X7 ATP receptor elevates 
mitochondrial calcium and potential, increases cellular ATP 
levels, and promotes serum-independent growth. Mol Biol 
Cell. 2005; 16:3260-72.
7. Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, Liu 
X, Su F, Lin L, Yao Y. miR-150 promotes human breast 
cancer growth and malignant behavior by targeting the 
pro-apoptotic purinergic P2X7 receptor. PLoS One. 2013; 
8:e80707.
8. Gehring MP, Kipper F, Nicoletti NF, Sperotto ND, Zanin 
R, Tamajusuku AS, Flores DG, Meurer L, Roesler R, Filho 
AB, Lenz G, Campos MM, Morrone FB. P2X7 receptor 
as predictor gene for glioma radiosensitivity and median 
survival. Int J Biochem Cell Biol. 2015; 68:92-100.
9. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, 
Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, Di 
Virgilio F. Expression of P2X7 receptor increases in vivo 
tumor growth. Cancer Res. 2012; 72:2957-69.
10. de Andrade Mello P, Filippi-Chiela EC, Nascimento J, 
Beckenkamp A, Santana DB, Kipper F, Casali EA, Nejar 
Bruno A, Paccez JD, Zerbini LF, Wink MR, Lenz G, Buffon 
A. Adenosine uptake is the major effector of extracellular 
ATP toxicity in human cervical cancer cells. Mol Biol Cell. 
2014; 25:2905-18.
11. Robinson LE, Shridar M, Smith P, Murrell-Lagnado RD. 
Plasma membrane cholesterol as a regulator of human and 
rodent P2X7 receptor activation and sensitization. J Biol 
Chem. 2014; 289:31983-94.
12. Nagy E, Balogi Z, Gombos I, Akerfelt M, Björkbom A, 
Balogh G, Török Z, Maslyanko A, Fiszer-Kierzkowska 
A, Lisowska K, Slotte PJ, Sistonen L, Horváth I, et al. 
Hyperfluidization-coupled membrane microdomain 
reorganization is linked to activation of the heat shock 
response in a murine melanoma cell line. Proc Natl Acad 
Sci U S A. 2007; 104:7945-50.
13. Gombos I, Crul T, Piotto S, Güngör B, Török Z, Balogh 
G, Péter M, Slotte JP, Campana F, Pilbat AM, Hunya A, 
Tóth N, Literati-Nagy Z, et al. Membrane-lipid therapy 
in operation: the HSP co-inducer BGP-15 activates stress 
Oncotarget67266www.impactjournals.com/oncotarget
signal transduction pathways by remodeling plasma 
membrane rafts. PLoS One. 2011; 6:e28818.
14. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins 
I, Kroemer G, Smyth MJ, Zitvogel L. Tumor cell death and 
ATP release prime dendritic cells and efficient anticancer 
immunity. Cancer Res. 2010; 70:855-8.
15. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, 
Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, 
Perfettini JL, Schlemmer F, Tasdemir E, et al. Activation 
of the NLRP3 inflammasome in dendritic cells induces 
IL-1beta-dependent adaptive immunity against tumors. Nat 
Med. 2009; 15:1170-8.
16. Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani 
AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano 
D, Pinton P, Jorgensen NR, Abelli L, et al. Accelerated 
tumor progression in mice lacking the ATP receptor P2X7. 
Cancer Res. 2015; 75:635-44.
17. Fang WG, Pirnia F, Bang YJ, Myers CE, Trepel JB. 
P2-purinergic receptor agonists inhibit the growth of 
androgen-independent prostate carcinoma cells. J Clin 
Invest. 1992; 89:191-6.
18. Wang Q, Wang L, Feng YH, Li X, Zeng R, Gorodeski 
GI. P2X7 receptor-mediated apoptosis of human cervical 
epithelial cells. Am J Physiol Cell Physiol. 2004; 
287:C1349-58.
19. Li X, Zhou L, Feng YH, Abdul-Karim FW, Gorodeski GI. 
The P2X7 receptor: a novel biomarker of uterine epithelial 
cancers. Cancer Epidemiol Biomarkers Prev. 2006; 
15:1906-13.
20. Shabbir M, Ryten M, Thompson C, Mikhailidis D, 
Burnstock G. Purinergic receptor-mediated effects of ATP 
in high-grade bladder cancer. BJU Int. 2008; 101:106-12.
21. Deli T, Csernoch L. Extracellular ATP and cancer: an 
overview with special reference to P2 purinergic receptors. 
Pathol Oncol Res. 2008; 14:219-31.
22. Shabbir M, Burnstock G. Purinergic receptor-mediated 
effects of adenosine 5’-triphosphate in urological malignant 
diseases. Int J Urol. 2009; 16:143-50.
23. Tamajusuku AS, Villodore ES, Paulus R, Coutinho-Silva 
R, Battasstini AM, Wink MR, Lenz G. Characterization of 
ATP-induced cell death in the GL261 mouse glioma. J Cell 
Biochem. 2010; 109:983-91.
24. Feng L, Sun X, Csizmadia E, Han L, Bian S, Murakami T, 
Wang X, Robson SC, Wu Y. Vascular CD39/ENTPD1 directly 
promotes tumor cell growth by scavenging extracellular 
adenosine triphosphate. Neoplasia. 2011; 13:206-16.
25. Gehring MP, Pereira TC, Zanin RF, Borges MC, Braga 
Filho A, Battastini AM, Bogo MR, Lenz G, Campos MM, 
Morrone FB. P2X7 receptor activation leads to increased 
cell death in a radiosensitive human glioma cell line. 
Purinergic Signal. 2012; 8:729-39.
26. Engin K, Leeper DB, Tupchong L, Waterman FM, 
Mansfield CM. Thermoradiation therapy for superficial 
malignant tumors. Cancer. 1993; 72:287-96.
27. Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic 
Z, Yu D, Sanders LL, Dewhirst MW. Randomized trial of 
hyperthermia and radiation for superficial tumors. J Clin 
Oncol. 2005; 23:3079-85.
28. Cihoric N, Tsikkinis A, van Rhoon G, Crezee H, Aebersold 
DM, Bodis S, Beck M, Nadobny J, Budach V, Wust P, 
Ghadjar P. Hyperthermia-related clinical trials on cancer 
treatment within the ClinicalTrials.gov registry. Int J 
Hyperthermia. 2015; 31:609-14.
29. Luk K, Francis M, Perez CA, Johnson RJ. Combined 
radiation and hyperthermia: comparison of two treatment 
schedules based on data from a registry established by the 
Radiation Therapy Oncology Group (RTOG). Int J Radiat 
Oncol Biol Phys. 1984; 10:801-9.
30. Irish CE, Brown J, Galen WP, Gallucci JJ, Hyman MD, 
Horowitz IJ, Snedecor PA, Baker HW. Thermoradiotherapy 
for persistent cancer in previously irradiated fields. Cancer. 
1986; 57:2275-9.
31. Seegenschmiedt MH, Sauer R, Miyamoto C, Chalal 
JA, Brady LW. Clinical experience with interstitial 
thermoradiotherapy for localized implantable pelvic tumors. 
Am J Clin Oncol. 1993; 16:210-22.
32. Van den Berg CA, Van de Kamer JB, De Leeuw AA, 
Jeukens CR, Raaymakers BW, van Vulpen M, Lagendijk JJ. 
Towards patient specific thermal modelling of the prostate. 
Phys Med Biol. 2006; 51:809-25.
33. Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola 
J, Wang Q, Bornstein BA, Hynynen K, Kaplan ID. 
Hyperthermia combined with radiation for the treatment 
of locally advanced prostate cancer: long-term results from 
Dana-Farber Cancer Institute study 94–153. Cancer. 2011; 
117:510-6.
34. Moros EG, Peñagaricano J, Novàk P, Straube WL, Myerson 
RJ. Present and future technology for simultaneous 
superficial thermoradiotherapy of breast cancer. Int J 
Hyperthermia. 2010; 26:699-709.
35. Zagar TM, Oleson JR, Vujaskovic Z, Dewhirst MW, 
Craciunescu OI, Blackwell KL, Prosnitz LR, Jones 
EL. Hyperthermia combined with radiation therapy for 
superficial breast cancer and chest wall recurrence: a 
review of the randomised data. Int J Hyperthermia. 2010; 
26:612-7.
36. Vasanthan A, Mitsumori M, Park JH, Zhi-Fan Z, Yu-Bin 
Z, Oliynychenko P, Tatsuzaki H, Tanaka Y, Hiraoka M. 
Regional hyperthermia combined with radiotherapy for 
uterine cervical cancers: a multi-institutional prospective 
randomized trial of the international atomic energy agency. 
Int J Radiat Oncol Biol Phys. 2005; 61:145-53.
37. Franckena M, van der Zee J. Use of combined radiation and 
hyperthermia for gynecological cancer. Curr Opin Obstet 
Gynecol. 2010; 22:9-14.
38. Huilgol NG, Gupta S, Dixit R. Chemoradiation with 
hyperthermia in the treatment of head and neck cancer. Int 
J Hyperthermia. 2010; 26:21-5.
Oncotarget67267www.impactjournals.com/oncotarget
39. Huilgol NG, Gupta S, Sridhar CR. Hyperthermia with 
radiation in the treatment of locally advanced head and 
neck cancer: a report of randomized trial. J Cancer Res 
Ther. 2010; 6:492-6.
40. Bae H, Kim HJ. Clinical outcomes of extracorporeal shock 
wave therapy in patients with secondary lymphedema: a 
pilot study. Ann Rehabil Med. 2013; 37:229-34.
41. Cebicci MA, Sutbeyaz ST, Goksu SS, Hocaoglu S, Oguz A, 
Atilabey A. Extracorporeal shock wave therapy for breast 
cancer-related lymphedema: a pilot study. Arch Phys Med 
Rehabil. 2016; 97:1520-5.
42. Pennacchioli E, Fiore M, Gronchi A. Hyperthermia as an 
adjunctive treatment for soft-tissue sarcoma. Expert Rev 
Anticancer Ther. 2009; 9:199-210.
43. Rastrelli M, Campana LG, Valpione S, Tropea S, Zanon 
A, Rossi CR. Hyperthermic isolated limb perfusion in 
locally advanced limb soft tissue sarcoma: a 24-year 
single-centre experience. Int J Hyperthermia. 2016; 
32:165-72.
44. Yamada K, Fukao Y, Hayashi M, Fukazawa M, Suzuki 
I, Nishimura M. Cytosolic HSP90 regulates the heat 
shock response that is responsible for heat acclimation in 
Arabidopsis thaliana. J Biol Chem. 2007; 282:37794-804.
45. Hoyt LR, Ather JL, Randall MJ, DePuccio DP, Landry 
CC, Wewers MD, Gavrilin MA, Poynter ME. Ethanol and 
other short-chain alcohols inhibit NLRP3 inflammasome 
activation through protein tyrosine phosphatase stimulation. 
J Immunol. 2016; 197:1322-34.
46. Vigh L, Escribá PV, Sonnleitner A, Sonnleitner M, Piotto S, 
Maresca B, Horváth I, Harwood LJ. The significance of lipid 
composition for membrane activity: new concepts and ways 
of assessing function. Prog Lipid Res. 2005; 44:303-44.
47. Vigh L, Torok Z, Balogh G, Glatz A, Piotto S, Horvatah 
I. (2007). Membrane-Regulated Stress Response. In: 
Csermely P, Vigh L (eds) Molecular Aspects of the Stress 
Response: Chaperones, Membranes and Networks, 
Springer, New York, USA, pp 114-131.
48. Vacca F, Amadio S, Sancesario G, Bernardi G, Volonté C. 
P2X3 receptor localizes into lipid rafts in neuronal cells. J 
Neurosci Res. 2004; 76:653-61.
49. Vial C, Evans RJ. Disruption of lipid rafts inhibits P2X1 
receptor-mediated currents and arterial vasoconstriction. J 
Biol Chem. 2005; 280:30705-11.
50. Garcia-Marcos M, Pochet S, Marino A, Dehaye JP. P2X7 
and phospholipid signalling: the search of the “missing 
link” in epithelial cells. Cell Signal. 2006; 18:2098-104.
51. Barth K, Weinhold K, Guenther A, Young MT, Schnittler H, 
Kasper M. Caveolin-1 influences P2X7 receptor expression 
and localization in mouse lung alveolar epithelial cells. 
FEBS J. 2007; 274:3021-33.
52. Rassendren F, Buell GN, Virginio C, Collo G, North RA, 
Surprenant A. The permeabilizing ATP receptor, P2X7. 
Cloning and expression of a human cDNA. J Biol Chem. 
1997; 272:5482-6.
53. Skarratt KK, Fuller SJ, Sluyter R, Dao-Ung LP, Gu BJ, 
Wiley JS. A 5’ intronic splice site polymorphism leads to 
a null allele of the P2X7 gene in 1-2% of the Caucasian 
population. FEBS Lett. 2005; 579:2675-8.
54. Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder 
S. Identification and characterization of splice variants 
of the human P2X7 ATP channel. Biochem Biophys Res 
Commun. 2005; 332:17-27.
55. Feng YH, Li X, Wang L, Zhou L, Gorodeski GI. A truncated 
P2X7 receptor variant (P2X7-j) endogenously expressed 
in cervical cancer cells antagonizes the full-length P2X7 
receptor through hetero-oligomerization. J Biol Chem. 
2006; 281:17228-37.
56. Feng YH, Li X, Zeng R, Gorodeski GI. Endogenously 
expressed truncated P2X7 receptor lacking the C-terminus 
is preferentially upregulated in epithelial cancer cells 
and fails to mediate ligand-induced pore formation and 
apoptosis. Nucleosides Nucleotides Nucleic Acids. 2006; 
25:1271-6.
57. Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Müller 
CE, Murakami T, Robson SC. CD39/ENTPD1 expression 
by CD4+Foxp3+ regulatory T cells promotes hepatic 
metastatic tumor growth in mice. Gastroenterology. 2010; 
139:1030-40.
58. Moeckel D, Jeong SS, Sun X, Broekman MJ, Nguyen 
A, Drosopoulos JH, Marcus AJ, Robson SC, Chen R, 
Abendschein D. Optimizing human apyrase to treat arterial 
thrombosis and limit reperfusion injury without increasing 
bleeding risk. Sci Transl Med. 2014; 6:248ra105.
59. Sun X, Han L, Seth P, Bian S, Li L, Csizmadia E, Junger 
WG, Schmelzle M, Usheva A, Tapper EB, Baffy G, 
Sukhatme VP, Wu Y, et al. Disordered purinergic signaling 
and abnormal cellular metabolism are associated with 
development of liver cancer in Cd39/Entpd1 null mice. 
Hepatology. 2013; 57:205-16.
60. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, 
Zinkernagel A, Nizet V, Insel PA, Junger WG. ATP release 
guides neutrophil chemotaxis via P2Y2 and A3 receptors. 
Science. 2006; 314:1792-95.
61. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, 
Insel PA, Junger WG. Ectonucleoside triphosphate 
diphosphohydrolase 1 (E-NTPDase1/CD39) regulates 
neutrophil chemotaxis by hydrolyzing released ATP to 
adenosine. J Biol Chem. 2008; 283:28480-6.
62. Casas-Pruneda G, Reyes JP, Pérez-Flores G, Pérez-Cornejo 
P, Arreola J. Functional interactions between P2X4 and 
P2X7 receptors from mouse salivary epithelia. J Physiol. 
2009; 587:2887-901.
63. Wu Y, Sun X, Kaczmarek E, Dwyer KM, Bianchi E, 
Usheva A, Robson SC. RanBPM associates with CD39 
and modulates ecto-nucleotidase activity. Biochem J. 2006; 
396:23-30.
Oncotarget67268www.impactjournals.com/oncotarget
64. Eskelinen EL, Schmidt CK, Neu S, Willenborg M, Fuertes 
G, Salvador N, Tanaka Y, Lüllmann-Rauch R, Hartmann 
D, Heeren J, von Figura K, Knecht E, Saftig P. Disturbed 
cholesterol traffic but normal proteolytic function in 
LAMP-1/LAMP-2 double-deficient fibroblasts. Mol Biol 
Cell. 2004; 15:3132-45.
